SCHEMBL6090310

SCHEMBL6090310

COc1ccc(C2NC(=O)c3cccc4c3N2CCC4=O)cc1O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
KDM4E B2RXH2 7/20 0.40
GAA P10253 2/20 0.40
CYP19A1 P11511 3/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
MAPK1 P28482 2/20 0.40
LMNA P02545 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
AR P10275 1/20 0.40
ALDH1A1 P00352 6/20 0.39
HPGD P15428 4/20 0.39
HSD17B10 Q99714 2/20 0.39
TP53 P04637 2/20 0.39
CYP3A4 P08684 2/20 0.39
XDH P47989 2/20 0.39
ATM Q13315 2/20 0.39
PKM P14618 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6091282 0.92 KDM4E (0.48) MAPTMEN1KMT2AL3MBTL1KDM4E
SCHEMBL6088925 0.90 ALDH1A1 (0.48) MAPTKMT2AKDM4EGAASMN1; SMN2
SCHEMBL6091130 0.88 KDM4E (0.39) MAPTMEN1KMT2AKDM4EGAA
SCHEMBL6092154 0.88 GAA (0.40) MAPTMEN1KMT2AKDM4EGAA
SCHEMBL6090132 0.88 ALDH1A1 (0.41) MAPTMEN1KMT2AKDM4EGAA
SCHEMBL6091358 0.88 KDM4E (0.39) MAPTKDM4EGAASMN1; SMN2TDP1
SCHEMBL6090909 0.87 MAPT (0.40) MAPTMEN1KMT2AL3MBTL1KDM4E
SCHEMBL6090914 0.87 MAPT (0.40) MAPTMEN1KMT2AL3MBTL1KDM4E
SCHEMBL6092303 0.85 KDM4E (0.39) MAPTKMT2AKDM4EGAASMN1; SMN2
SCHEMBL6089743 0.84 LMNA (0.44) MAPTMEN1KMT2AL3MBTL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004028-A1 Novel PARP inhibitor MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
EP-1582520-A1 NOVEL PARP INHIBITORS MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2005-10-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004028-A1 Novel PARP inhibitor PARP1, PARP2, PARP11 MAPT 497/4885MEN1 2771/4885KMT2A 274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.